Holen Sie sich die Stockscreener-App
74.93
1.91%
-1.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$76.39
Offen:
$77.25
24-Stunden-Volumen:
1.26M
Relative Volume:
0.50
Marktkapitalisierung:
$10.49B
Einnahmen:
$1.09B
Nettoeinkommen (Verlust:
$233.57M
KGV:
48.71
EPS:
1.5382
Netto-Cashflow:
$327.01M
1W Leistung:
+6.84%
1M Leistung:
+22.78%
6M Leistung:
+85.88%
1J Leistung:
+435.98%
1-Tages-Spanne:
$73.61
$77.90
1-Wochen-Bereich:
$68.97
$77.90
52-Wochen-Spanne:
$12.44
$77.90
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
74.93 | 10.49B | 1.09B | 233.57M | 327.01M | 1.5382 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
ViaSat, Arrowhead Pharmaceuticals, and Sphere Entertainment Lead Stock Returns - Markets Mojo
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD - Investing.com
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Canada
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan
JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com
MSN Money - MSN
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - Business Wire
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - Yahoo Finance
Arrowhead upgraded at Morgan Stanley on upcoming catalysts - MSN
Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge? - Sahm
Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - Insider Monkey
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc. - MarketBeat
ARWR Initiates Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by JPMorgan Chase & Co. - MarketBeat
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
J.P. Morgan Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $88 - Moomoo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating - Investing.com
JP Morgan Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Overweight Recommendation - MSN
Arrowhead Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
5 Most Profitable Biotech Stocks to Buy Now - Insider Monkey
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Behavioral Patterns of ARWR and Institutional Flows - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday - MarketBeat
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Vanguard reports 5.05% stake in Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Pictet Asset Management Holding SA - MarketBeat
Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead - Stock Titan
FengHe Fund Management Pte. Ltd. Makes New $17.71 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - msn.com
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe - marketscreener.com
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead Pharmaceuticals (ARWR) price target increased by 23.01% to 77.60 - MSN
Insider Sell: James Hamilton Sells 10,000 Shares of Arrowhead Ph - GuruFocus
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock - MarketBeat
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 pre-planned shares - Stock Titan
Arrowhead CFO Daniel Apel sells $934,285 in company stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock - Investing.com UK
Arrowhead CFO Daniel Apel sells $934,285 in company stock - Investing.com
Arrowhead (ARWR) CFO Apel sells 13,095 shares in Rule 10b5-1 trades - Stock Titan
BlackRock holds 12.2% of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in 13G/A - Stock Titan
Sanofi, Arrowhead, Novartis win CHMP backing (SNY:NASDAQ) - Seeking Alpha
Arrowhead (ARWR) Secures Positive EMA Opinion for REDEMPLO in FC - GuruFocus
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):